Skip to main content
Premium Trial:

Request an Annual Quote

SpectruMedix and Capital Genomix to Couple, Co-Market Products for Gene-Expression Analysis

NEW YORK, May 4 (GenomeWeb News) - SpectruMedix of State College, Pa., and Capital Genomix of Gaithersburg, Md., will market and distribute Capital's gene expression-analysis platform for capillary electrophoresis-based applications, the companies said today.


The two partners plan to couple Capital's GeneSystem320, which allows researchers to detect gene transcripts at very low levels, with SpetruMedix's Reveal Genetic Analysis system, which uses high-throughput capillary electrophoresis for genetic analyses. They intend to release a new product early in the third quarter.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.